Get the Stockscreener App
3.025
1.85%
0.055
Whitehawk Therapeutics Inc stock is traded at $3.025, with a volume of 238.05K.
It is up +1.85% in the last 24 hours and down -26.04% over the past month.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
See More
Previous Close:
$2.97
Open:
$2.98
24h Volume:
238.05K
Relative Volume:
0.66
Market Cap:
$172.45M
Revenue:
$7.15M
Net Income/Loss:
$-20.60M
P/E Ratio:
6.3738
EPS:
0.4746
Net Cash Flow:
$-97.99M
1W Performance:
-12.82%
1M Performance:
-26.04%
6M Performance:
-22.44%
1Y Performance:
+44.05%
1-Day Range:
$2.98
$3.08
1-Week Range:
$2.941
$3.57
52-Week Range:
$1.87
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Name
Whitehawk Therapeutics Inc
Sector
Industry
Phone
551-321-2234
Address
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
3.025 | 172.45M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 128.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.59 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.61 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-26 | Initiated | Stifel | Buy |
| Jul-13-26 | Initiated | Leerink Partners | Outperform |
| Jun-25-26 | Initiated | B. Riley Securities | Buy |
| Feb-05-26 | Initiated | Oppenheimer | Outperform |
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Whitehawk Therapeutics Inc Stock (WHWK) Latest News
Whitehawk Therapeutics, Inc. (WHWK) Stock Price History & Data - Traders Union
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages - MarketBeat
Eledon Pharmaceuticals (Nasdaq:ELDN)Stock Analysis - Simply Wall Street
Whitehawk Therapeutics (WHWK) Ticks Up 0.53% to $3.76 as Shares Hold Above Key SupportThematic ETF Flow - https://www.siam.in/
Insiders At Whitehawk Therapeutics Sold US$2.5m In Stock, Alluding To Potential Weakness - simplywall.st
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know - Eastern Progress
Whitehawk (WHWK) clarifies CSO RSU vesting terms - Stock Titan
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update - MarketBeat
Whitehawk Therapeutics Insider Iyengar Vijay K Receives 76,080 Derivative Securities on September 9, 2026 - Kalkine Media
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
A lung cancer target stayed largely stable after treatment. Whitehawk is testing a targeted drug. - Stock Titan
Whitehawk Therapeutics Adds Oncology Leader to Board - The Globe and Mail
Whitehawk Therapeutics appoints Vijay Iyengar to board By Investing.com - Investing.com South Africa
Whitehawk Therapeutics appoints Vijay Iyengar to board By Investing.com - Investing.com Nigeria
Whitehawk Therapeutics Adds Oncology Leader to Board - TipRanks
Oncology veteran Vijay Iyengar joins Whitehawk Therapeutics (WHWK) board - Stock Titan
Whitehawk Therapeutics appoints Vijay Iyengar to board - investing.com
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, To Board Of Directors - TradingView
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors - PR Newswire
Five brands, more than 20 countries. Whitehawk adds an oncology leader to its board. - Stock Titan
BlackRock Inc. Makes New $8.81 Million Investment in Whitehawk Therapeutics, Inc. $WHWK - marketbeat.com
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
Montanova Capital LLC Has $19.69 Million Position in Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know - qz.com
WHWK | Whitehawk Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Whitehawk (WHWK) Shares: Finishes 2.31% Up at $4.87 on the Day; Next Test: the $4.63 to $5.11 Range Remains in FocusCall Resistance - vinanet.vn
Whitehawk (WHWK) Watch: Gains 2.94% to Reach $4.90 in the Latest Session; Range Check: $4.66 and $5.15 Define the Nearby Reference Levels at the CloseRetail Driven Moves - Vinanet
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
WHWK Q2 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Rise 4.04%Net Profit Margin - vinanet.vn
WHWK Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 33.73% EPS Surprise, Shares Rise 4.04% - vinanet.vn
Whitehawk Therapeutics (WHWK) Jumps 4.5% to $4.66, Edges Toward Key ResistanceBackspread Trade - vinanet.vn
Whitehawk Therapeutics (WHWK) Jumps 4.5% to $4.66, Edges Toward Key ResistancePrice Surge Stocks - dars.gov.et
Whitehawk Therapeutics (WHWK) Drops 4.7% to $4.46, Approaches Key Support at $4.24Diagonal Spread Trade - vinanet.vn
Whitehawk Therapeutics (WHWK) Drops 4.7% to $4.46, Approaches Key Support at $4.24Vanna Flow - dars.gov.et
Whitehawk Therapeutics (WHWK) Drops 4.7% to $4.46, Approaches Key Support at $4.24Breadth Thrust - careplusvn.com
Whitehawk Therapeutics (WHWK) Drops 4.7% to $4.46, Approaches Key Support at $4.24Gap Fill Strategy - dars.gov.et
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) Stock Price, News & Analysis - Kalkine
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) Stock Price, News & Analysis - kalkine.ca
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Whitehawk Therapeutics (WHWK): OrbiMed entities disclose 3.93M-share, 7.3% ownership stake - Stock Titan
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform - Yahoo Finance
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineGeographic Revenue Trends - vinanet.vn
Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Aadi Bioscience Inc (3350.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Whitehawk Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Whitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - tradingview.com
Whitehawk Therapeutics Inc Stock (WHWK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Whitehawk Therapeutics Inc Stock (WHWK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER |
Apr 15 '26 |
Sale |
3.86 |
77,000 |
297,220 |
436,824 |
| Giacobello Scott M. | Officer |
Apr 15 '26 |
Proposed Sale |
3.85 |
233,766 |
899,999 |
0 |
| BALL BRYAN | See remarks |
Apr 14 '26 |
Sale |
3.64 |
92,460 |
336,554 |
397,106 |
| BALL BRYAN | See remarks |
Apr 13 '26 |
Sale |
3.46 |
26,389 |
91,306 |
489,566 |
| BALL BRYAN | See remarks |
Apr 10 '26 |
Sale |
3.43 |
6,596 |
22,624 |
515,955 |
| BALL BRYAN | See remarks |
Apr 09 '26 |
Sale |
3.57 |
50,000 |
178,500 |
522,551 |
| Lennon David James | CHIEF EXECUTIVE OFFICER |
Apr 09 '26 |
Sale |
3.38 |
14,500 |
49,010 |
518,622 |
| BALL BRYAN | Officer |
Apr 09 '26 |
Proposed Sale |
3.30 |
196,969 |
649,998 |
0 |
| Lennon David James | Officer |
Apr 09 '26 |
Proposed Sale |
3.38 |
4,364 |
14,750 |
0 |
| Lennon David James | CHIEF EXECUTIVE OFFICER |
Apr 08 '26 |
Sale |
3.40 |
63,945 |
217,413 |
533,122 |
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):